TP-3654
- Generic Name
- TP-3654
- Brand Names
- Relyvrio
- Drug Type
- Small Molecule
- Chemical Formula
- C22H25F3N4O
- CAS Number
- 1361951-15-6
- Unique Ingredient Identifier
- EOB0N7BOY4
- Background
Tauroursodeoxycholic acid, also known as ursodoxicoltaurine, is a highly hydrophilic tertiary bile acid that is produced in humans at a low concentration. It is a taurine conjugate of ursodeoxycholic acid with comparable therapeutic efficacy and safety, but a much higher hydrophilicity. Normally, hydrophilic bile acids regulates hydrophobic bile acids and ...
- Indication
Tauroursodeoxycholic acid is used to prevent and treat gallstone formation.
Tauroursodeoxycholic acid is used in combination with phenylbutyric acid to treat amyotrophic lateral sclerosis (ALS) in adults.
- Associated Conditions
- Amyotrophic Lateral Sclerosis (ALS), Gallstones
- Associated Therapies
- -
Targeting Endoplasmic Reticulum Stress in Human Hypertension
- First Posted Date
- 2023-09-06
- Last Posted Date
- 2023-09-06
- Lead Sponsor
- University of North Texas Health Science Center
- Target Recruit Count
- 70
- Registration Number
- NCT06025630
- Locations
- 🇺🇸
University of North Texas Health Science Center, Fort Worth, Texas, United States
Open Label Extension of TUDCA-ALS Study
- Conditions
- Interventions
- First Posted Date
- 2023-03-03
- Last Posted Date
- 2023-03-03
- Lead Sponsor
- Humanitas Mirasole SpA
- Target Recruit Count
- 184
- Registration Number
- NCT05753852
- Locations
- 🇧🇪
Katholieke Universiteit Leuven, Leuven, Belgium
🇮🇹AOU Città della Salute e della Scienza di Torino, Torino, Italy
🇬🇧University of Sheffield, Sheffield, United Kingdom
The Clinical Application of Tauroursodeoxycholic Acid in Patients With Liver Fibrosis.
- First Posted Date
- 2021-01-27
- Last Posted Date
- 2021-03-09
- Target Recruit Count
- 60
- Registration Number
- NCT04727320
Trial of Tauroursodeoxycholic Acid (TUDCA) in Asthma
- First Posted Date
- 2019-03-18
- Last Posted Date
- 2019-09-16
- Lead Sponsor
- University of Vermont
- Target Recruit Count
- 11
- Registration Number
- NCT03878654
- Locations
- 🇺🇸
Vermont Lung Center, Colchester, Vermont, United States
Safety and Efficacy of TUDCA as add-on Treatment in Patients Affected by ALS
- Conditions
- Interventions
- First Posted Date
- 2019-01-11
- Last Posted Date
- 2023-07-10
- Lead Sponsor
- Humanitas Mirasole SpA
- Target Recruit Count
- 337
- Registration Number
- NCT03800524
- Locations
- 🇩🇪
Alfried Krupp Krankenhaus Rüttenscheid, Essen, Germany
🇩🇪Medizinische Hochschule Hannover, Hannover, Germany
🇬🇧The Walton Centre NHS Foundation Trust, Liverpool, United Kingdom
Study of TP-3654 in Patients With Advanced Solid Tumors
- First Posted Date
- 2018-10-23
- Last Posted Date
- 2023-11-14
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT03715504
- Locations
- 🇺🇸
Huntsman Cancer Institute, Salt Lake City, Utah, United States
🇺🇸MD Anderson, Houston, Texas, United States
🇺🇸University of Virginia, Charlottesville, Virginia, United States
A Trial of Bile Acid Supplementation in Patients With Multiple Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2018-02-06
- Last Posted Date
- 2023-05-03
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 59
- Registration Number
- NCT03423121
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
The Discovery of the Double Sphincter in Gallbladder
- First Posted Date
- 2013-11-28
- Last Posted Date
- 2016-03-08
- Target Recruit Count
- 150
- Registration Number
- NCT01998451
- Locations
- 🇨🇳
The Discovery of the Double Sphincter in Gallbladder, Guiyang, Guizhou, China
Tauroursodeoxycholic Acid for Protease-inhibitor Associated Insulin Resistance
- Conditions
- Interventions
- First Posted Date
- 2013-06-13
- Last Posted Date
- 2020-01-27
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 27
- Registration Number
- NCT01877551
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Effect of Endoplasmic Reticulum Stress on Metabolic Function
- Conditions
- Interventions
- First Posted Date
- 2008-10-15
- Last Posted Date
- 2018-05-29
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 101
- Registration Number
- NCT00771901
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.